Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial

Giustina, 2020, Multidisciplinary management of acromegaly: a consensus, Rev Endocr Metab Disord, 21, 667, 10.1007/s11154-020-09588-z Melmed, 2020, Pituitary-tumor endocrinopathies, New Eng J Med, 382, 937, 10.1056/NEJMra1810772 Fleseriu, 2021, A Pituitary Society update to acromegaly management guidelines, Pituitary, 24, 1, 10.1007/s11102-020-01091-7 Biermasz, 2019, The burden of disease for pituitary patients, Best Pract Res Clin Endocrinol Metab, 33, 10.1016/j.beem.2019.101309 Broersen, 2021, Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis, J Clin Endocrinol Metab, 106, 577, 10.1210/clinem/dgaa868 Dichtel, 2021, Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly, Clin Endocrinol (Oxf), 94, 58, 10.1111/cen.14309 Fleseriu, 2021, Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands, Front Endocrinol (Lausanne), 12, 10.3389/fendo.2021.627711 Geer, 2020, Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice, BMC Endocr Disord, 20, 117, 10.1186/s12902-020-00595-4 Liu, 2018, Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly, J Investig Med, 66, 653, 10.1136/jim-2017-000570 Strasburger, 2016, Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly, Eur J Endocrinol, 174, 355, 10.1530/EJE-15-1042 Webb, 2017, Management of endocrine disease: quality of life tools for the management of pituitary disease, Eur J Endocrinol, 177, R13, 10.1530/EJE-17-0041 Melmed, 2015, Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial, J Clin Endocrinol Metab, 100, 1699, 10.1210/jc.2014-4113 Samson, 2020, Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide, J Clin Endocrinol Metab, 105, e3785, 10.1210/clinem/dgaa526 Fleseriu, 2020, An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies, Pituitary, 23, 347, 10.1007/s11102-020-01038-y Reilly, 1993, The validity and reproducibility of a work productivity and activity impairment instrument, Pharmacoeconomics, 4, 353, 10.2165/00019053-199304050-00006 Colao, 2020, Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study, J Endocrinol Invest, 43, 529, 10.1007/s40618-019-01138-y Fleseriu M, Melmed S, Mangal B, Strasburger C, Biermasz N. Longitudinal assessment of response to treatment with oral octreotide capsules in patients with acromegaly: post hoc analysis of a phase 3 trial. European Congress of Endocrinology, Munich, Germany; May 28–31, 2016 (poster). Gadelha, 2019, Systemic complications of acromegaly and the impact of the current treatment landscape: an update, Endocr Rev, 40, 268, 10.1210/er.2018-00115 Pruessner, 2003, Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change, Psychoneuroendocrinology, 28, 916, 10.1016/S0306-4530(02)00108-7 Matta, 2011, Clinical and metabolic characteristics of acromegalic patients with high IGF1/normal GH levels during somatostatin analog treatment, Eur J Endocrinol, 164, 885, 10.1530/EJE-11-0098 Milani, 2004, Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development, J Clin Endocrinol Metab, 89, 2271, 10.1210/jc.2003-032150 Skjaerbaek, 2000, Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency, Clin Endocrinol (Oxf), 52, 25, 10.1046/j.1365-2265.2000.00876.x Baldelli, 2000, Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg), J Clin Endocrinol Metab, 85, 4099 Chieffo, 2013, Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly, J Clin Endocrinol Metab, 98, 4047, 10.1210/jc.2013-2262 Sheppard, 2015, Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study, Pituitary, 18, 385, 10.1007/s11102-014-0585-6 Tutuncu, 2012, Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly, Pituitary, 15, 398, 10.1007/s11102-011-0335-y Klingenberg, 2014, A new and improved confidence interval for the Mantel-Haenszel risk difference, Stat Med, 33, 2968, 10.1002/sim.6122 Nurminen Bevan, 2002, Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size, J Clin Endocrinol Metab, 87, 4554, 10.1210/jc.2001-012012 Carmichael, 2014, Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis, J Clin Endocrinol Metab, 99, 1825, 10.1210/jc.2013-3757 McKeage, 2003, Octreotide long-acting release (LAR): a review of its use in the management of acromegaly, Drugs, 63, 2473, 10.2165/00003495-200363220-00014 Biermasz, 2017, New medical therapies on the horizon: oral octreotide, Pituitary, 20, 149, 10.1007/s11102-016-0785-3 Geer, 2020, Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider, Pituitary, 23, 140, 10.1007/s11102-019-01013-2 Tuvia, 2012, Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression, J Clin Endocrinol Metab, 97, 2362, 10.1210/jc.2012-1179